Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207408 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
A Phase 2 study of Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis, sponsored by Dynavax Technologies Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 3
- Study locations
NCT07207408: Recruiting Phase 2 study of Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis, sponsored by Dynavax Technologies Corporation.
NCT07207408 is a Phase 2 study of Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis that is actively recruiting participants, run by Dynavax Technologies Corporation. The registered enrollment target is 148 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07207408, a Phase 2 study of Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis, is actively recruiting participants, sponsored by Dynavax Technologies Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
Conditions Studied
Interventions
- BIOLOGICAL rF1V-1018
Study Locations (3)
Florida
- AMR- Miami - Miami
Kansas
- AMR- El Dorado - El Dorado
Nevada
- AMR- Las Vegas - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2026-10-16 |
| Phase | Phase 2 |
What NCT07207408 shows while recruiting
NCT07207408 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis appearing as the primary indexed condition, and to 1 intervention - of which rF1V-1018 is the first listed.
NCT07207408 reports a single indexed study location in Florida, Kansas, Nevada.
Frequently Asked Questions
What is clinical trial NCT07207408 about?
NCT07207408 is a clinical study titled "Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age". This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
What is the current status of trial NCT07207408?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2025-09-11. Estimated completion is 2026-10-16.
What conditions does trial NCT07207408 study?
This clinical trial studies the following conditions: Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis.
What interventions are being tested in trial NCT07207408?
The interventions under investigation include: rF1V-1018 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07207408?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207408 being conducted?
This trial has 3 study locations across Florida, Kansas, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07207408's enrollment target sits among peer trials
148 491st of 2000 higher than 1,506 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI